

## Clinical and laboratory characteristics of adults with chronic kidney disease in Jos, Nigeria

Oche O. Agbaji<sup>1\*</sup>, Augustine O. Ebonyi<sup>\*\*</sup>, Zumnan M. Gimba<sup>\*</sup>, Esala E. Abene<sup>\*\*\*</sup>, Monday O Ogiator<sup>\*\*\*\*</sup>, Emmanuel I. Agaba<sup>\*</sup>

\* Renal Unit, Department of Medicine, University of Jos/ Jos University Teaching Hospital, Jos. Nigeria,

\*\* Department of Paediatrics, University of Jos/ Jos University Teaching Hospital, Jos. Nigeria,

\*\*\* Department of Medicine, Dalhatu Araf Specialist Hospital, Lafia, Nigeria,

\*\*\*\* Department of Medicine, Benue State University Teaching Hospital, Makurdi, Nigeria

**Corresponding Author:** Dr Oche O. Agbaji, Department of Medicine, Jos University Teaching Hospital, P.M.B.2076, Jos, Nigeria. Email: [oagbaji@yahoo.com](mailto:oagbaji@yahoo.com)

### Abstract

#### Background:

Chronic kidney disease (CKD) affects between 10 to 16% of the population globally. In

Nigerians, it is the most common mode of presentation of patients with renal disease. We

describe the clinical and laboratory characteristics of adults diagnosed with CKD at the Jos

University Teaching Hospital (JUTH). Identifying these characteristics would help create more awareness among health workers on the nature of CKD in our setting.

#### Methods:

This was a descriptive retrospective study on 81 patients aged 16-88 years, in which patients' data were extracted from their case notes over a period of 3 years (January 2008 to December 2010). The median and interquartile range (IQR) for continuous variables and the frequency and percentages of CKD across categorical variables, were determined

**Results:** The median age of the patients was 38 years (IQR, 29 - 50) and majority were males

(49, 60.5%). The median eGFR of the patients was low, 12 ml/min/1.73m<sup>2</sup> (IQR, 7 -25). Majority were ≤40years of age (45, 55.6%) and had stage 2 systolic hypertension (40/81, 49.4%) and stage 2 diastolic hypertension (49/81, 60.5%), a diagnosis of chronic glomerulonephritis (35/81, 43.2%), anaemia (PCV<24%) (59/75,78.7%), urea level >6.5 mmol/L (70/79, 88.6%), serum creatinine level >126.0 μmol/L (69/75, 92%), uric acid level >420 μmol/L (33/45, 73.3%) and proteinuria (53/71, 74.7%).

**Conclusion:** CKD was commoner in young adults. The majority of patients had very low eGFR with anaemia as the commonest complication; suggesting late presentation. There is therefore the need for education of health workers on the importance of early and timely referral of CKD patients to nephrologists. A thorough evaluation of CKD patients, early detection and treatment of complications associated with advanced CKD should also be emphasized.

### Introduction

Chronic kidney disease (CKD) affects between 10 to 16% of the population globally.<sup>1</sup> In Africa, the lack of renal registries means that there are no reliable statistics about the prevalence of CKD in most African countries; few studies have however estimated the incidence to be less

than 100 per million population.<sup>2, 3</sup> In most African countries, CKD mainly affects the young aged between 20 to 50 years. CKD affects between 1.6 to 12.4% of Nigerians and is the most common mode of presentation of patients with renal disease.<sup>4, 5, 6</sup>

Various factors have been found to cause CKD, the most common of such factors in sub Saharan Africa (SSA) include: hypertension (HTN), infection related-chronic glomerulonephritis (CGN), diabetes mellitus (DM), and human immunodeficiency virus infection (HIV)<sup>2, 7</sup>. Of these factors, HTN is one of the most important. Hypertension has been shown to have a strong, graded association with CKD, especially in men<sup>8</sup>.

We describe the clinical and laboratory characteristics of adults diagnosed with CKD at the Jos University Teaching Hospital. Identifying such characteristics could help create more awareness among health workers on the nature of CKD in our setting.

## **Methods**

### **Study design**

This was a descriptive retrospective study in which patient data was extracted from their case notes over a period of 3 years from January 2008 to December 2010

### **Study subjects**

These were adults aged 16 – 88 years diagnosed with CKD at JUTH during the period of the study. In this study CKD was defined as kidney damage or decreased glomerular filtration rate (GFR) of less than 60ml/min/1.73m<sup>2</sup>.<sup>1</sup>

### **Study site**

The study was undertaken in the medical out-patient clinic and medical wards at JUTH, Jos, Nigeria.

### **Clinical and Laboratory methods**

The blood pressure (BP) of patients was measured on two different occasions using a mercury sphygmomanometer in the sitting position, with the patient calm. The average of two readings was taken as the BP. Blood pressure was classified based on the JNC 7 classification<sup>9</sup>. The body mass index (BMI) of

each patient was calculated from their height and weight using the formula: Weight (kg)/ Height (M<sup>2</sup>).

Abdominal ultrasound scan (USS) was used to determine kidney size, echogenicity and cortico-medullary differentiation (CMD) and the presence of any kidney cysts. Calyceal, ureteric and bladder dilatations were also determined using USS. Blood glucose level was determined using glucose oxidase method<sup>10</sup>. Blood lipids (serum cholesterol, high density lipoprotein, low density lipoprotein and triglyceride), uric acid and serum creatinine were measured using an C 311 chemistry autoanalyzer (Roche Diagnostics, Mannheim, Germany). The presence of protein and blood in urine was determined using Combi-10 Urinalysis strips. While haemoglobin (Hb) and packed cell volume (PCV) levels were measured using the Mindray BC-3200 haematology autoanalyser (Roche Diagnostics, Mannheim, Germany). The estimated glomerular filtration rate (eGFR) was calculated using the modification of diet in renal disease (MDRD) formula<sup>11</sup>. All the clinical, radiological and laboratory values were obtained at the point of diagnosis of CKD.

### **Ethical Consideration.**

Ethical approval for the study was obtained from the research and ethics Committee of JUTH.

### **Statistical analysis**

Data analysis was performed using Stata software version 10.0 (Stata Corporation, College Station, Texas, USA). The median and interquartile range (IQR) was determined for all continuous variables as these were not normally distributed. The body mass index (BMI) was calculated using Stata by the formula: Weight (kg)/ Height (M<sup>2</sup>). The continuous variables (FBS, BP, Hb, PCV, eGFR, BMI, cholesterol, creatinine, urea and uric acid levels) were also categorized into categorical variables using appropriate cut off points as follows: FBS  $\geq 6.5$  mmol/L as DM, Systolic  $\geq 140$  mmHg and Diastolic  $\geq 90$  mmHg as HTN, PCV < 36% (Hb < 12 g/dL) in females or PCV < 39% (Hb < 13 g/dL) in Males as anaemia in patients with CKD<sup>12</sup>, eGFR < 60 ml/min/1.73m<sup>2</sup> as evidence of CKD, BMI (18.5-24.9, 25.0-29.9, and  $\geq 30$  kg/m<sup>2</sup> which is considered as obesity),

cholesterol >6.5 mmol/L as hypercholestromia, while creatinine  $\geq$ 126  $\mu$ mol/L, urea >6.5 mmol/L and uric acid >420  $\mu$ mol/L indicate elevated levels. The frequency and percentages of CKD across the various categorical variables were determined. Patients with missing data were excluded from the analysis.

### Results

There were a total of 81 adult patients with CKD. Their median age was 38 years (IQR, 29 - 50) and majority were males (49, 60.5%), the Male: Female ratio being 1.5. The median duration of illness at the time of presentation was 1 month (IQR, 0.5 - 12). Their median

systolic BP was high, 150 mmHg (IQR, 140 - 180) and so was their diastolic BP, 110 mmHg (90-110). Their mean BMI was within normal limits, 22.5 kg/m<sup>2</sup> (IQR, 20.8-26.5). The patients had a high median serum creatinine, urea and uric acid levels: 503  $\mu$ mol/L (IQR, 236 - 903), 20.6 mmol/L (IQR, 10.8 - 33.1) and 530  $\mu$ mol/L (419 - 637), respectively. The median eGFR of the patients was very low, 12 ml/min/1.73m<sup>2</sup> (IQR, 7 -25) and median Hb was also low, 9.8 g/dL (IQR, 7.7-12) while their median FBS, PCV and serum cholesterol were within normal limits: 5.2 mmol/L (IQR, 4.8 - 6.5), 31% (25 - 36), 5.4 mmol/L (4.6-6.1), respectively (Table 1).

**Table 1. Clinical and laboratory characteristics of adults with chronic kidney disease at the Jos University Teaching Hospital, Jos**

Characteristic	N (%)*
<b>Age (years)</b>	
$\leq$ 40	45 (55.6)
>40	36 (44.4)
Median (IQR)	38 (29-50)
Missing**	0 (0.0)
<b>Sex</b>	
Female	32 (39.5)
Male	49 (60.5)
Missing	0 (0.0)
<b>Duration of illness at presentation (months)</b>	
Median (IQR)	1 (0.5-12)
Missing	8 (9.9)
<b>Accompanying diagnosis</b>	
Glomerulonephritis	35(43.2)

Hypertension	26 (32.2)
Diabetes mellitus	10 (12.4)
Autosomal dominant polycystic kidney disease	6 (7.4)
Acute renal failure	1 (1.2)
Obstructive uropathy	1 (1.2)
Nephrotic syndrome	1 (1.2)
Posterior uretral valve	1 (1.2)
Missing	0 (0.0)
<b>Systolic blood pressure (mmHg)</b>	
<140	17 (21.0)
≥140	64 (79.0)
Median (IQR)	150 (140-180)
Missing	0 (0.0)
<b>Diastolic blood pressure (mmHg)</b>	
<90	18 (22.2)
≥90	63 (77.8)
Median (IQR)	100 (90-110)
Missing	0 (0.0)
<b>Body mass index (kg/m<sup>2</sup>)</b>	
<18.5 (Underweight)	0 (0.0)
18.5-24.9	15 (62.5)
25.0-29.9	7 (29.2)
≥30 (Obesity)	2 (8.3)
Median (IQR)	22.5 (20.8-26.5)
Missing	57 (70.4)
<b>Packed cell volume† (%)</b>	
≥36 or ≥39	18 (24.0)
<36or <39 (Anaemia)	57 (76.0)

Median (IQR)	31 (25-36)
Missing	6 (7.4)
<b>Haemoglobin (g/dL)</b>	
≥12 or ≥13	11 (22.4)
<12 or 13 (Anaemia)	38 (77.5)
Median (IQR)	9.8 (7.7-12)
Missing	32 (39.5)
<b>Fasting blood glucose (mmol/L)</b>	
<6.5	27 (75.0)
≥6.5	9 (25)
Median (IQR)	5.3 (4.9-6.4)
Missing	45 (55.5)
<b>Serum cholesterol (mmol/L)</b>	
≤6.5	48 (78.7)
>6.5	13 (21.3)
Median (IQR)	5.4 (3.7-6.4)
Missing	20 (24.7)
<b>Estimated glomerular filtration rate (mls/minute)</b>	
≥60	6 (7.5)
<60	74 (92.5)
Median (IQR)	12 (7-25)
Missing	1 (1.2)
<b>Serum creatinine (μmol/L)</b>	
≤126	6 (8.0)
>126	69 (92.0)
Median (IQR)	503 (236-903)
Missing	6 (7.4)
<b>Serum urea (mmol/L)</b>	

≤6.5	9 (11.4)
>6.5	70 (88.6)
Median (IQR)	20.6 (10.8-33.1)
Missing	2 (2.5)
<b>Serum uric acid (μmol/L)</b>	
≤420	12 (26.7)
>420	33 (73.3)
Median (IQR)	530 (419-637)
Missing	36 (44.4)
<b>Right kidney size (cm)</b>	
Median (IQR)	9.5 (8.6-10.8)
Missing	1 (1.2)
<b>Left kidney size (cm)</b>	
Median (IQR)	9.7 (8.5-10.9)
Missing	0 (0.0)
<b>Renal echogenicity</b>	
Normal	18 (23.4)
Increased	59 (76.6)
Missing	4 (4.9)
<b>Increased corticomedullary differentiation</b>	
Normal	29 (39.2)
Increased	45 (60.8)
Missing	7 (8.6)
<b>Renal cyst</b>	
Absent	70 (86.4)
Present	11 (13.6)
Missing	0 (0.0)

<b>Calyceal dilatation</b>	73 (90.1)
Absent	8 (9.9)
Present	0 (0.00)
Missing	
<b>Ureteric dilatation</b>	
Absent	76 (98.7)
Present	1 (1.3)
Missing	4 (4.9)
<b>Bladder dilatation</b>	
Absent	77 (100)
Present	0 (0.00)
Missing	4 (4.9)
<b>Urinary protein</b>	
Absent	18 (25.3)
Present	53 (74.7)
Missing	10 (12.3)
<b>Blood in urine</b>	
Absent	53(81.5)
Present	12 (18.5)
Missing	16 (19.8)

\*Data are presented as No. (%) or median (interquartile range).

\*\*Missing values for each variable shown are the number (%) out of a total of 81 patients

†Anaemia was defined as PCV<36% (Hb <12 g/dL) in females or PCV <39% (Hb <13 g/dL) in Males

Majority of the patients were  $\leq 40$  years of age (45, 55.6%) and had: systolic BP  $\geq 140$  mmHg (64/81, 79.0%), diastolic BP  $\geq 90$  mmHg (63/81, 77.8%), an eGFR of  $< 60$  ml/minute (74/81, 92.5%), a diagnosis of chronic glomerulonephritis (CGN) (35/81, 43.2%), a normal FBS level (27/36, 75.0%), anaemia (PCV<36% or 39%) (57/75, 76%), increased renal echogenicity (59/77, 76.2%), a poor renal

CMD (45/74, 60.8%), urea level  $> 6.5$  mmol/L (70/79, 88.6%), serum creatinine level  $> 126.0$   $\mu$ mol/L (69/75, 92%), uric acid level  $> 420$   $\mu$ mol/L (33/45, 73.3%) and proteinuria (53/71, 74.7%). Also, majority of the patients did not have: haematuria (53/65, 81.5%), hypercholesterolaemia (48/, 78.7%), calyceal dilatation (73/81, 90.1%), ureteric dilatation

(76/77, 98.7%), bladder dilatation (77/77, 100%). Only 2 patients (8.3%) had obesity. Based on the JCN 7 classification of BP, majority of the patients with CKD had a stage 2

systolic hypertension (40/81, 49.4%) and stage 2 diastolic hypertension (49/81, 60.5%) (Table 2).

**Table 2. Blood pressure levels in adults with chronic kidney disease at the Jos University Teaching Hospital, Jos**

Blood pressure classification*	Total N (%)
<b>Normal</b>	
SBP (<120 mmHg)	7 (8.6)
DBP (<80 mmHg)	8 (9.9)
<b>Prehypertension</b>	
SBP (120-139 mmHg)	10 (12.3)
DBP (80-89 mmHg)	10 (12.3)
<b>Stage 1 hypertension</b>	
SBP (140-159 mmHg)	24 (29.6)
DBP (90-99 mmHg)	14 (17.3)
<b>Stage 2 hypertension</b>	
SBP ( $\geq$ 160 mmHg)	40 (49.4)
DBP ( $\geq$ 100 mmHg)	49 (60.5)

\*Classification was based on the JCN 7 classification of BP

SBP = Systolic blood pressure. DBP = Diastolic blood pressure. mmHg = Millimeters of mercury

## Discussion

Majority of the CKD patients seen were young, had chronic glomerulonephritis as the underlying cause of their CKD, stage 2 hypertension, anaemia and a reduced eGFR with an accompanying elevation of serum urea, creatinine and uric acid levels.

The finding that CKD was commoner in young adults in their economically productive years is consistent with previous studies in SSA. This is at variance with the finding in developed countries where CKD is commoner among middle aged and elderly people<sup>2,7</sup>. Hypertension, which was found in majority of our patients, is one of the leading risk factors for the development of CKD in SSA. There is a strong association between CKD and hypertension where each can cause or aggravate the other, thus the control of elevated blood pressure is important in all stages of CKD

regardless of aetiology<sup>2,7,13</sup>. Majority of the patients had BMI that was normal with only 2 (8.3%) having BMI  $\geq$ 30 kg/m<sup>2</sup> (obesity) and this may be because about 57/81 had missing values for BMI. Obesity and underweight has been established as a contributing factor for the increased morbidity and mortality in patients with advanced CKD<sup>14</sup>.

Most of our patients had advanced CKD with low eGFR; this could be an indication of late referral to a nephrologist, a situation similar to other previous studies in Nigeria<sup>15,16,17</sup>. Late referral is known to be associated with higher mortality in CKD<sup>18</sup>. Anaemia was common among our patients, similar to the finding by Shittu et al<sup>19</sup>. Anaemia contributes to the acute deterioration in patients with CKD. Also, anaemia contributes significantly to the increased mortality among CKD patients, and



supports the late presentation among our patients<sup>12</sup>.

One of the limitations of this study, which used data that was retrospectively collected, was that some variables had missing values, which has resulted in the underestimation of the frequency (proportion) of certain patient characteristics.

### Conclusion

In our experience, CKD occurred more in young adults who presented late with advanced CKD and attendant complications like anaemia. We recommend more education of other health workers on the need for early referral of CKD patients to the Nephrologists for appropriate management. The need for thorough evaluation of CKD patients, early detection and treatment of complications associated with advanced CKD cannot be overemphasized.

**Conflict of Interest:** None

### References

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney inter., Suppl.* 2013; 3: 1–150.
2. Naicker S. End –Stage renal disease in sub Saharan Africa. *Kidney inter suppl.* 2013; 3: 161-163
3. Nalado AM, Abdu A, Muhammed H et al. Prevalence and risk factors for chronic kidney disease among civil servants in Kano. *Niger J Basic Clin Sci* 2012; 9: 70-4
4. Egbi OG, Okafor UH, Miebodei KE et al. Prevalence and correlates of chronic kidney disease among civil servants in Bayelsa state Nigeria. *Niger J Clin Pract* 2014; 17: 602-7
5. Odubanjo MO, Oluwasola AO, Kadiri S. The epidemiology of end stage renal disease in Nigeria: the way forward. *Int Urol Nephrol* 2011; 43: 785-92
6. Agaba EI, Agbaji OO, Anteyi A. Pattern of renal diseases in north central Nigeria. *J Med Trop* 2002; 4: 33-37
7. Arogundade FA, Barsoum RS. CKD prevention in Sub- Saharan Africa: a call for governmental, nongovernmental and community support. *Am J Kidney Dis* 2008; 51: 515-23.
8. Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington county, Maryland. *J Am Soc Nephrol* 2003; 14: 2934-2941
9. The seventh report of the joint national committee on the prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. Available at [www.nhlbi.nih.gov/guidelines/hypertension/index/htm](http://www.nhlbi.nih.gov/guidelines/hypertension/index/htm). Accessed on 15 December 2014.
10. Bishop ML, Fody EP, Schoeff LE et al. *Clinical Chemistry Techniques, Principles, Correlations* 6<sup>th</sup> Edition, Lippincot Williams and Wilkins 2010. Philadelphia PA: 262-350.
11. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predictive equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med.* 1999; 130: 461-70.
12. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for anemia in Chronic Kidney Disease. *Kidney inter., Suppl.* 2012; 2: 279-335.
13. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of blood pressure in Chronic Kidney Disease. *Kidney inter., Suppl.* 2012; 2: 337–414.
14. Verukonda RK, Zhu TY, Yip T, Lui SL, Lo WK. Body Mass Index and mortality risk in Asian peritoneal dialysis patients in Hong Kong- Impact of diabetes and cardiovascular disease status. *Perit. Dial Int* 2014; 34: 390-398.

15. Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO. Diseases causing chronic renal failure in Nigerians: a prospective study of 100 cases. *Afr J Med Med Sci.* 1989 18:131-7.
16. Akinsola A, Akinkugbe OO, chronic renal failure in the tropics, clinical features and strategies in management. *Postgraduate Doctor.* 1989; 12: 1118-1130.
17. Kadiri S, Arije A. Temporal variations and metrological factors in hospital admissions of chronic renal failure in south west Nigeria. *West Afr J Med* 1999; 18: 49-51.
18. Kazmi WH, Obrador GT, Khan SS. Late Nephrology referral and mortality among patients with end stage renal disease: a propensity score analysis. *Nephrol Dial Transplant* 2004; 14: 2934-2941.
19. Shittu AO, Chijioke A, Billiaminu SA. Haematological profile of patients with chronic kidney disease in Nigeria. *J Nephrol Renal Transpl* 2013; 5: 2-10.